Protecting the unprotected.
This is the idea at the heart of the EIMPRIS Study. People with cancer face so many challenges with their treatment and overall quality of life. One of the most concerning is that their immune systems can be highly compromised as they go through their cancer treatments. This can leave them unprotected against SARS-CoV-2 even after receiving vaccines and boosters. The EIMPRIS Study was created by a group of hematologists and oncologists looking for a treatment that could protect cancer patients from contracting the SARS-CoV-2 virus.
Click the video below to learn more about this important study.
Protecting the unprotected.
This is the idea at the heart of the EIMPRIS Study. People with cancer face so many challenges with their treatment and overall quality of life. One of the most concerning is that their immune systems can be highly compromised as they go through their cancer treatments. This can leave them unprotected against SARS-CoV-2 even after receiving vaccines and boosters. The EIMPRIS Study was created by a group of hematologists and oncologists looking for a treatment that could protect cancer patients from contracting the SARS-CoV-2 virus.
Click the video below to learn more about this important study.
If you enroll in the EIMPRIS program, you will receive two doses of Evusheld™—one at the beginning of the program and the second, 6 months later. Your health status will be monitored for 12 months using customized surveys. You will complete these surveys using your smart phones, tablets, computer or personally, via a live call-center. Laboratory samples will also be collected at pre-defined time intervals that will likely coincide with your scheduled office visits that are part of your cancer treatment.
Evusheld™ has been approved by the FDA under an Emergency Use Authorization (EUA) and is now considered to be part of the “standard of care” to prevent the SARS-CoV-2 infection. Please know that all the information that you provide in the EIMPRIS program is confidential and “de-identified”—meaning it will be impossible to identify you by name, your health status or any other descriptor. Your privacy is protected.
Research sites across the country will be enrolling 1500 patients in this study. We encourage you to ask your doctor if they are participating in the EIMPRIS study. If they are, we hope that you will enroll. If they are not a participating site, you may want to suggest that they reach out to the program’s management team at the contact below.
Research sites across the country will be enrolling 1500 patients in this study. We encourage you to ask your doctor if they are participating in the EIMPRIS study. If they are, we hope that you will enroll. If they are not a participating site, you may want to suggest that they reach out to the program’s management team at the contact below.
Contact us
If you are a hematologist/oncologist and would like to join our research team, please contact us here using the contact form.
Also, click the video below if you would like to hear more about the study from its Principal Investigator.
Who is MediMergent?
MediMergent, the Real-World Evidence Company, builds and deploys innovative technologies to collect information directly from patients, unfiltered by any third party. In support of the “Voice of the Patient”, MediMergent collects and integrates multiple sources of patient related data from other stakeholders including patients’ medical records, pharmacy fill and refill data, health insurance claims, labs and images as well as data collected from wearable devices used by the patient. This comprehensive database, used in the national EIMPRIS program, provides an unprecedented and robust picture of the quality of life of immuno-compromised cancer patients, their treatment to prevent SARS-CoV-2 infection, and the impact of these neutralizing antibodies on the healthcare delivery system.
Join the EIMPRIS Study today. Reduce your Risk.
Protect yourself and those who care about you.
The information in this website is not intended to provide medical advice. It does not replace a conversation with your healthcare provider or a member of the study team. If you have unanswered questions after exploring this website, ask your healthcare provider or a member of the study team. This website does not contain answers about your diagnosis or provide any other medical information about your treatment. Also, it is not intended for reporting problems—sometimes called “adverse events”—that you may experience if you participate in EIMPRIS.